Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
736 participants
INTERVENTIONAL
2023-01-01
2026-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In-line filtration is increasingly used in critically-ill infants but its benefits, by preventing micro-particle infusion in neonates, remain to be demonstrated.
In-line filters in the intravenous administration sets prevent the infusion of particles, which may reduce infectious complications.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This particulate consists of metals, drug crystals, glass fragments or cotton fibres and can be generated by drug packaging, incomplete reconstitution and chemical incompatibilities.
Filters have been shown to remove micro-organisms, endotoxin, air and particles in critically-ill adults and older infants, but its benefits in newborn remain to be demonstrated.
Although recommendations for the use of in-line intravenous filters have been published, there is no consensus on their use.
Moreover, 50% of inflammatory episodes in the setting of NICU are blood culture-negative. These episodes could be partly related to the presence of particles in the infusion lines.
PROJECT AIMS AND DESIGN:
Aim of this multicenter trial is to evaluate the effectiveness of in-line filtration in reducing culture-negative inflammatory episodes in infants admitted to NICU. Further aim is to evaluate the efficacy in the reduction of main CVC-associated complications when using filters.
PATIENTS:
All infants admitted to the NICUs are considered eligible for inclusion into the trial if prolonged infusion therapy (one week or more) is expected, with either umbilical vein catheters (UVC) in a central position or percutaneously inserted central venous catheter. Infants in whom a peripheral UVC is placed but for whom infusion therapy via central venous access is planned will be enrolled too.
Exclusion criteria: Infants will be excluded from participation in the trial if they have clinical characteristics requiring transfer to units not participating in the study before discontinuation of infusion therapy (neurological or surgical diseases, chromosomal abnormalities, and major malformations)..
PROTOCOL:
After randomization each infant will be subsequently allocated to experimental group (Filter) or to control group (Control) as per randomization. Each research unit will refer to its own protocols for infection sulveillance and prevention, although respecting some minimal standard criteria and indications, common and approved by all research units.
In the filter group, all infusions, with the exception of some solutions (eg blood products), will be subjected to filtration. The aqueous solutions (parenteral therapy and drugs) will be administered through 0.2 μm filters which will be replaced every 96 h; the lipid emulsions will be administered through 1.2 μm filters which will be replaced every 24 h. In case of emergency, life-saving drugs will be administered with bolus modality though the infusion line closer to the patient without the need for filtration. In case of drugs/solutions not supported by filtration (eg blood products), they will be administered through a dedicated unfiltered access, which will be removed as soon as the drug is no longer needed.
In the control group, all infusion will be administered through unfiltered accesses.
Data will be collected daily from enrolment up to 48 h after discontinuation of infusion therapy.
In case of inflammatory episode, all patients will undergo to defined specimens, as always in correct clinical practice: complete blood count, sepsis biomarkers (C- reactive protein, procalcitonin, presepsin) and blood culture.
At discharge information regarding the main neonatal pathologies will be recorded.
MAIN OUTCOME Frequency of patients with at least one inflammatory episode sepsis-like, defined by alteration of the biomarkers of inflammation in a negative-culture contest.
SECONDARY OUTCOMES
* Frequency of patients with at least one inflammatory episode defined by alteration of the biomarkers of inflammation in a positive-culture contest.
* Occurrence of phlebitis or local cutaneous inflammation
* Occurrence of luminal obstruction and/or extravascular fluid effusion
* Duration of mechanical ventilation
* Number of catheter days
* Length of stay
* Neonatal mortality
SAMPLE SIZE:
The baseline risk of inflammatory states in the target population remains undetermined. However, we hypothesize a range between 30% and 35%. Consequently, a median risk of 32.5% was assumed for the control group. With the application of filters, a plausible 30% risk reduction is anticipated, resulting in an estimated risk of 22.75% in the intervention arm. Utilizing Fisher's exact test to compare two independent proportions, with an alpha of 0.05, a power of 0.80, and a 1:1 group allocation, the calculated minimum sample size required for significance is 349 infants for each arm, leading to a total of N=698 infants. Accounting for an estimated 5% dropout rate during follow-up, the adjusted minimum sample size becomes N=736 infants"
DATA ANALYSIS:
Data will be analysed according to an intention-to-treat model. Therefore, data from all infants enrolled into the study will be considered for the analysis. Death and transfer to another hospital before discontinuation of infusion therapy, are the only two reasons for exclusion. The primary outcome will be evaluated by Fisher's exact test. Secondary outcomes will be evaluated by Fisher's exact test or appropriate generalized linear models.
EXPECTED RESULTS AND IMPACT ON CLINICAL PRACTICE:
If the use of in-line filters resulted in a significant decrease in negative-culture inflammatory episodes and/or in any other complications, the use of in-line filters in all intravenous administration systems may be recommended in NICU.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control
Patients with central venous access (central umbilical venous catheter or epicutaneous cava catheter)
No interventions assigned to this group
Filter
Patients with central venous access and in-line filters (central umbilical venous catheter or epicutaneous cava catheter)
In-line filter
All infusions, with the exception of some solutions (eg blood products), will be subjected to filtration. The aqueous solutions (parenteral therapy and drugs) will be administered through 0.2 μm filters which will be replaced every 96 h; the lipid emulsions will be administered through 1.2 μm filters which will be replaced every 24 h.
In case of emergency, life-saving drugs will be administered with bolus modality though the infusion line closer to the patient without the need for filtration.
In case of drugs/solutions not supported by filtration (eg blood products), they will be administered through a dedicated unfiltered access, which will be removed as soon as the drug is no longer needed.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
In-line filter
All infusions, with the exception of some solutions (eg blood products), will be subjected to filtration. The aqueous solutions (parenteral therapy and drugs) will be administered through 0.2 μm filters which will be replaced every 96 h; the lipid emulsions will be administered through 1.2 μm filters which will be replaced every 24 h.
In case of emergency, life-saving drugs will be administered with bolus modality though the infusion line closer to the patient without the need for filtration.
In case of drugs/solutions not supported by filtration (eg blood products), they will be administered through a dedicated unfiltered access, which will be removed as soon as the drug is no longer needed.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
1 Hour
3 Months
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pall Corporation
OTHER
University of Turin, Italy
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Francesco Cresi, MD, PhD
Study Director
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Francesco Cresi, PhD MD
Role: STUDY_DIRECTOR
University of Turin, Italy
Alessandra Coscia, PhD MD
Role: STUDY_DIRECTOR
University of Turin, Italy
Elena Maggiora, MD
Role: PRINCIPAL_INVESTIGATOR
University of Turin, Italy
Cecilia Capetti, MD
Role: PRINCIPAL_INVESTIGATOR
University of Turin, Italy
Francesca De Matteis, RN
Role: PRINCIPAL_INVESTIGATOR
Città della salute e della Scienza di Torino
Martina Capitanio, MD
Role: PRINCIPAL_INVESTIGATOR
University of Turin, Italy
Fabio Mosca, Prof.
Role: STUDY_CHAIR
University of Milan, Italy
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Città della Salute e della Scienza
Torino, Italia, Italy
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Francesco Cresi, MD, PhD
Role: primary
Elena Maggiora, MD
Role: backup
References
Explore related publications, articles, or registry entries linked to this study.
van den Hoogen A, Krediet TG, Uiterwaal CS, Bolenius JF, Gerards LJ, Fleer A. In-line filters in central venous catheters in a neonatal intensive care unit. J Perinat Med. 2006;34(1):71-4. doi: 10.1515/JPM.2006.009.
Sasse M, Dziuba F, Jack T, Koditz H, Kaussen T, Bertram H, Beerbaum P, Boehne M. In-line Filtration Decreases Systemic Inflammatory Response Syndrome, Renal and Hematologic Dysfunction in Pediatric Cardiac Intensive Care Patients. Pediatr Cardiol. 2015 Aug;36(6):1270-8. doi: 10.1007/s00246-015-1157-x. Epub 2015 Apr 7.
Virlouvet AL, Pansiot J, Toumazi A, Colella M, Capewell A, Guerriero E, Storme T, Rioualen S, Bourmaud A, Biran V, Baud O. In-line filtration in very preterm neonates: a randomized controlled trial. Sci Rep. 2020 Mar 19;10(1):5003. doi: 10.1038/s41598-020-61815-4.
Jack T, Boehne M, Brent BE, Hoy L, Koditz H, Wessel A, Sasse M. In-line filtration reduces severe complications and length of stay on pediatric intensive care unit: a prospective, randomized, controlled trial. Intensive Care Med. 2012 Jun;38(6):1008-16. doi: 10.1007/s00134-012-2539-7. Epub 2012 Apr 12.
Foster JP, Richards R, Showell MG, Jones LJ. Intravenous in-line filters for preventing morbidity and mortality in neonates. Cochrane Database Syst Rev. 2015 Aug 6;2015(8):CD005248. doi: 10.1002/14651858.CD005248.pub3.
Eschborn S, Weitkamp JH. Procalcitonin versus C-reactive protein: review of kinetics and performance for diagnosis of neonatal sepsis. J Perinatol. 2019 Jul;39(7):893-903. doi: 10.1038/s41372-019-0363-4. Epub 2019 Mar 29.
van Lingen RA, Baerts W, Marquering AC, Ruijs GJ. The use of in-line intravenous filters in sick newborn infants. Acta Paediatr. 2004 May;93(5):658-62. doi: 10.1111/j.1651-2227.2004.tb02993.x.
Worthington P, Gura KM, Kraft MD, Nishikawa R, Guenter P, Sacks GS; ASPEN PN Safety Committee. Update on the Use of Filters for Parenteral Nutrition: An ASPEN Position Paper. Nutr Clin Pract. 2021 Feb;36(1):29-39. doi: 10.1002/ncp.10587. Epub 2020 Oct 22.
Cresi F, Maggiora E, Capetti C, Capitanio M, Ferroglio M, Spada E, De Matteis F, Cosimi S, Mosca F, Coscia A; INCAS Trial Research Group. Effect of in-line filtration in newborns: study protocol of the Intravenous Neonatal Central Access Safety (INCAS) randomized controlled trial. Trials. 2024 Jul 6;25(1):459. doi: 10.1186/s13063-024-08264-w.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
INCAS
Identifier Type: -
Identifier Source: org_study_id